Anil Achyuta is the Investment Managing Director at TDK Ventures, and also Investment Director for Fund EX1. He is passionate about the energy and healthcare sectors. He believes these are the most impactful areas in building a sustainable future, a mission that is directly in line with TDK Ventures’ goals.
Of his eleven investments, he has secured two exits: GenCell IPO’d on the Tel Aviv Stock Exchange (GNCL:IT), and Origin, which was acquired by the #1 3-D printing company in the world, Stratasys, for $100M.
Prior to TDK Ventures, Anil held leadership roles at Fortune 500 companies including L’Oréal, Johnson & Johnson, GlaxoSmithKline, and Draper.
Anil was voted one of the Rising Stars in 2021 by Venture Capital Journal and was ranked the #2 Rising Star in 2021 out of 20,000 corporate venture managers globally. He was also voted as one of the Emerging Leaders of 2022 by Global Corporate Venturing. He is a published author in polymer science, neural engineering, microfluidics, and tissue engineering with 11 peer-reviewed publications, two book chapters, and six US patents.
He has a Ph.D. in Chemical Engineering from Northeastern University and received his M.B.A. from the University of Florida Warrington College of Business.
Anil was born and raised in Bangalore, India in a family of teachers, and speaks fluent Kannada, Hindi. He loves sports and music. He was a former cricket player, and currently plays tennis, table tennis, racquetball, and cricket occasionally. He loves playing guitar and listening to classic rock.